We are live on ! Find out more
MATN

Mateon Therapeutics, Inc.
MATN

Delisted

MATN was delisted on the 7th of December, 2016.

Back to rankings

1 hedge funds and large institutions have $13K invested in Mateon Therapeutics, Inc. in 2020 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more capital invested

Capital invested by funds: $6K → $13K (+$7K)

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
+$5.58K

Top Sellers

No sellers this quarter

MATN Hedge Fund Activity: Q4 2020 in Review

1 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Mateon Therapeutics, Inc. (MATN) for Q4 2020, worth a combined $13K — up 117% from $6K a quarter earlier.

Fund positioning in MATN was balanced in Q4 2020: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was IFP Advisors, adding an estimated $5.58K.

  • 1 institutional investor held Mateon Therapeutics, Inc. (MATN) as of Q4 2020, unchanged from Q3 2020.
  • Funds reported $13K of Mateon Therapeutics, Inc. stock for Q4 2020, up 117% quarter-over-quarter.
  • 0 funds opened new Mateon Therapeutics, Inc. positions in Q4 2020 and 0 closed out.
  • The largest Mateon Therapeutics, Inc. buyer in Q4 2020 was IFP Advisors, an estimated $5.58K added.

Based on aggregated 13F filings for Q4 2020.